Skip to main content
ENGN
NASDAQ Life Sciences

enGene Holdings Secures Up To $125M Loan Facility, Extends Maturity, and Issues Warrants

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$9.34
Mkt Cap
$625.637M
52W Low
$2.65
52W High
$11.14
52W Position info
252% above low
Off High info
16% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ENGN has more than doubled off its 52-week low of $2.65.

Summary

enGene Holdings Inc. has amended its loan agreement with Hercules Capital, increasing its term loan facility from $50 million to $125 million and extending the maturity date to 2030, providing significant capital for operations.


Key Events · Financing and Capital Events · ENGN

  • Increased Loan Facility

    The term loan facility was expanded from $50 million to $125 million, providing substantial capital for the company's operations.

  • Extended Maturity Date

    The maturity date for the term loans has been extended to January 1, 2030, offering a longer repayment period.

  • Milestone-Based Tranches

    Additional loan tranches are contingent on achieving specific clinical and commercial milestones, including a clinical endpoint for EG-70 and net product revenue targets.

  • Warrant Issuance

    Warrants to purchase common shares were issued to lenders, representing potential future dilution. The initial warrants issued for the first tranche amount to 40,850 shares at an exercise price of $9.18.


Analysis · ENGN · Life Sciences

This substantial financing agreement provides enGene Holdings with access to up to $125 million, significantly bolstering its financial runway and supporting its clinical and commercial development efforts. The initial $25 million advance refinances existing debt, while subsequent tranches are contingent on achieving key clinical and commercial milestones, aligning financing with operational progress. While the facility introduces debt and potential dilution from warrants, securing such a large capital commitment is a critical positive for a life sciences company, enabling continued investment in its pipeline.

At the time of this filing, ENGN was trading at $9.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $625.6M. The 52-week trading range was $2.65 to $11.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ENGN - Latest Insights

ENGN
Jul 17, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.82
Real-time Price: $1.74 info
Change: -$0.082 (-5%) info
Market Cap: $117.901M info
ENGN
Jun 18, 2026, 4:06 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $1.72
Real-time Price: $1.74 info
Change: +$0.018 (+1%) info
Market Cap: $117.901M info
ENGN
Jun 15, 2026, 9:16 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.74
Real-time Price: $1.74 info
Change: -$0.0020 (-0.11%) info
Market Cap: $117.901M info
ENGN
Jun 15, 2026, 9:15 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $1.72
Real-time Price: $1.74 info
Change: +$0.018 (+1%) info
Market Cap: $117.901M info
ENGN
Jun 15, 2026, 9:14 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.72
Real-time Price: $1.74 info
Change: +$0.018 (+1%) info
Market Cap: $117.901M info